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Abstract
Chronic obstructive pulmonary disease (COPD) is a major contributor to hospitalizations
and healthcare costs in North America. While the hallmark of COPD is airflow limitation,
it is also associated with abnormalities of the cardiovascular system. Enlargement of the
pulmonary artery (PA) is a morphological marker of pulmonary hypertension, and was
previously shown to predict acute exacerbations using a one-dimensional (1D) diameter
measurement of the main PA.

We hypothesized that a three-dimensional (3D)

quantification of PA size would be more sensitive than 1D methods and encompass
morphological changes along the entire central PA.

Hence, we developed a 3D

measurement of the main (MPA), left (LPA) and right (RPA) pulmonary arteries as well
as total PA volume (TPA) volume from thoracic x-ray computed tomography (CT)
imaging. Three observers performed five repeated measurements for 15 ex-smokers. There
was a strong agreement (r2 = 0.76) between PA volume and PA diameter measurements,
which was used as the gold standard. Intra-rater measurement reproducibility was
evaluated by calculating the coefficient of variation (CV) using five rounds of
measurements and revealed excellent agreement (CV < 8%) between measurements. Interrater measurement variability was also evaluated using intraclass correlation analysis
which revealed strong agreement (ICCMPA=0.98) between observers.
In an application of this tool, we sought to explore the relationship between PA volumes
and lung structure-function as determined by spirometry, hyperpolarized helium-3
magnetic resonance imaging (MRI) and CT in 124 ex-smokers, with (n=68) and without
(n=56) airflow limitation, and in a control group of 35 healthy never-smokers. We
observed significantly greater MPA (p=.014), RPA (p=.001) and TPA (p=.003) volumes
in ex-smokers with airflow limitation when compared to ex-smokers without airflow
limitation.

We also observed significantly greater PA volumes in both ex-smoker

subgroups when compared with the never-smoker control group. Modest but significant
correlations were observed for PA volumes and measurements of lung structure and
function. However, this was not observed when analyzing ex-smokers with airflow
limitation alone, suggesting that pulmonary artery enlargement may occur secondary to
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COPD in our subject group.

Multivariate zero-inflated Poisson regression analysis

revealed TPA volume to be a significant (p=.03) predictor of acute exacerbations of COPD.
In conclusion, we developed a reproducible technique for quantifying the volume of the
PA. We showed that pulmonary artery enlargement may be secondary to COPD in our
subject group. We also showed that total pulmonary artery volume was a significant
predictor of COPD exacerbations and could be considered as a biomarker for predicting
the occurrence of exacerbation events. Automated measurements of pulmonary artery
abnormalities once developed, can be used to further evaluate healthy volunteers and
patients with COPD.
Keywords: Chronic obstructive pulmonary disease (COPD), cardiovascular disease,
pulmonary artery, enlargement, main pulmonary artery volume, left pulmonary artery
volume, right pulmonary artery volume, total pulmonary artery volume
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CHAPTER 1: INTRODUCTION
Individuals with Chronic Obstructive Pulmonary Disease (COPD) often experience acute
exacerbations which are severe events associated with an increase in morbidity and
mortality. Previous work1 demonstrated that abnormalities of the pulmonary artery are
predictive of these events; however, further research and better tools are needed to
strengthen this finding. The purpose of this chapter is to provide motivation for the work
presented in subsequent chapters and to provide an overview of pulmonary anatomy, lung
function, pulmonary artery anatomy and current biomarkers used to predict the occurrence
of acute exacerbations of COPD.

Overview
Chronic obstructive pulmonary disease (COPD) is a chronic, obstructive, inflammatory
disease affecting millions of individuals. It mainly manifests in elderly individuals who
have been exposed to tobacco smoke and air pollution for extended periods of time.2 These
toxins induce an inflammatory response in the lungs, resulting in a combination of small
airways disease (obstructive bronchiolitis) and parenchymal destruction (emphysema), the
extent of which varies among individuals.3 Persons with COPD are associated with a
decline in lung function and an increase in airflow limitation. As the disease progresses,
those with moderate-to-severe disease are likely to experience acute events known as
exacerbations, often resulting from bacterial or viral infections.4

These individuals

experience a reduced quality of life and seek immediate medical attention which often
results in hospitalization.

Costs associated with treatment substantially burden our

healthcare system. While COPD is preventable and treatable, it is very rarely reversible.
Current diagnosis relies on spirometry measurements as it is the most widely available
diagnostic tool that can provide global measurements of the lung.
Although the defining feature of COPD is airflow limitation, COPD is also associated with
vascular abnormalities such as coronary vascular disease, cerebrovascular disease5-8 and
pulmonary artery (PA) anomalies.1 Vascular disease is the leading cause of hospitalization
for individuals with mild to moderate cases of COPD and following cancer, it ranks as the
second leading cause of death.9, 10 Those with COPD can often develop mild cases of
pulmonary hypertension (PH), while some can progress to develop out of proportion PH,
which has also been linked to abnormalities in the PA.11 While previous studies have
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utilized a simple one-dimensional diameter measurement of the main PA (MPA) to
quantify its size, a more robust, three-dimensional (3D) measurement for assessing PA
volumes has not yet been developed. Thus, our goal was to develop 3D metrics to evaluate
the size of the main, left (LPA) and right (RPA) pulmonary arteries and to explore their
relationships with measurements of lung function and structure as determined by
spirometry, CT and hyperpolarized helium-3 magnetic resonance imaging (MRI) of the
lung.
The second chapter of this thesis focuses on the development of the 3D measurement for
quantifying MPA, LPA, RPA and total PA (TPA) volumes. Intra- and inter-observer as
well as longitudinal reproducibility was assessed and reported. The third chapter focuses
on the relationship between MPA, LPA, RPA and TPA volumes with measurements of
lung function and structure as well as on the ability of the 3D volumetric technique in
predicting future exacerbations of COPD. The fourth and final chapter of this thesis serves
as a summary. As well, it focuses on the limitations of the current techniques outlining
ideas that might be worth exploring in the future.

Burden of COPD
As outlined by The Global Burden of Disease set by the World Health Organization,
respiratory disease accounted for 6.8 and 6.9 percent of female and male deaths
worldwide.12

Furthermore, COPD has ranked as the fourth leading cause of death

worldwide accounting for 3.0 million or 5.1% of all deaths worldwide.12 In 2012, COPD
was ranked as the fourth leading cause of death in lower-middle income countries, next to
ischemic heart disease, stroke and lower respiratory infections, causing a total of 3.1
million deaths worldwide.13 To date, there are 64 million people who suffer from mild-tomoderate cases of COPD and this number is on the rise. Projections for 2030 predict COPD
to climb to be the third leading cause of death worldwide, accounting for 8.6% of all deaths,
a 3.5% increase from 2004 in total deaths due to COPD.14 The leading causes of death for
2004 and projections for 2030 are summarized in Table 1-1. Interestingly, vascular disease
is the single largest cause of hospitalization for individuals with mild-to-moderate cases of
COPD, and following lung cancer, the second leading cause of death.9, 10 In a recent study9
of 5887 middle-aged volunteers with asymptomatic airway obstruction who quit smoking
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at the baseline visit, 22% of subject deaths were caused by cardiovascular disease, second
to 33% of lung cancer deaths, 14.5 years into the study.9 Thus, it is important to consider
and explore in detail the relationship between COPD and cardiovascular disease to better
understand the mechanisms responsible for such outcomes.
Table 1-1 Leading causes of death as determined by the WHO.14
Disease or Injury
Ischemic heart disease
Cerebrovascular disease
Lower respiratory infections
COPD

2004
Deaths (%) Rank
12.2
1
9.7
2
7.0
3
5.1
4

2030
Rank Deaths (%)
1
14.2
2
12.1
4
3.8
8.6
3

Lung Structure and Function
Human cells require oxygen from the surrounding environment to produce energy in the
form of adenosine triphosphate (ATP) through a process called cellular respiration. A
byproduct of this process is carbon dioxide, which must be removed and released back into
the environment.15 The primary function of the lungs is gas exchange, delivering oxygen
from the environment into our circulating blood as well as removing carbon dioxide and
releasing it back into the environment.16 Figure 1-1 outlines the human airway tree, the
path inhaled air takes to reach the alveolar sacs (alveoli) of the lungs, where the majority
of gas exchange occurs. The airways are made up of branching tubes which become
progressively narrower and shorter and increase in number towards the alveolar sacs.16
Airways can be divided into two major categories, those in the conducting zone and those
in the respiratory zone. Conducting airways are responsible for transporting air to smaller
airways where gas exchange can take place. Conducting airways are not responsible for
gas exchange as they do not contain alveoli.16 Respiratory airways however contain alveoli
and therefore are responsible for gas exchange. Most of the gas exchange occurs in the
alveoli which are the most distal part of the airway tree.16 The following subchapters will
outline the roles of the conducting and respiratory airways in more detail.

1.3.1

Conducting zone

The conducting zone is comprised of the upper and lower airways. The upper airways
include the nose, oral cavity, pharynx and the larynx.17 They are responsible for being the
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primary conductors of air, for warming and humidifying the inspired air and for preventing
foreign materials from entering the airways.17 Following the upper airways, inhaled air
travels through the lower airways (conducting airways) which in general include the first
16 generations (orders) of the tracheobronchial tree.16, 17 As shown in Figure 1-1, the
airway tree starts off at generation zero, or the trachea, which then divides into the left and
right main bronchi which enter the left and right lung respectively.16 The airway tree
continues dividing in a dichotomous fashion, meaning that every mother branch bifurcates
into two daughter branches, that can be different in size, first into bronchioles and then the
terminal bronchioles.15, 16, 18 The terminal bronchioles are generally the 16th generation
airways and are the final airways that make up the conducting zone. Besides directing air
to the respiratory zone, the conducting airways further warm and humidify the inhaled air
to make it more efficient for gas exchange. The walls of these airways are generally
composed of three different layers. The inner epithelial layer is lined with epithelial cells
that are equipped with cilia and numerous mucus glands. These form the mucociliary
escalator and work together to expel foreign particles.15, 17 Trapped particles in the mucus
travel upstream at a rate of about 2 mm/s to the pharynx, where the mucus is swallowed.15
The middle layer of the wall is a smooth muscle layer while the outermost layer is
composed of connective tissue containing supportive cartilage.15 Both layers provide the
conductive airways’ rigidity and support. Due to the lack of alveoli, the conductive airways
do not play a role in gas exchange. Thus, they constitute the anatomic dead space which
is about 150 mL in volume.16

1.3.2

Respiratory zone

The respiratory zone is comprised of airway generations 17 to 23. The respiratory
bronchioles are the first airways to form alveoli and therefore some of the gas exchange
occurs in these airways.16 As shown in Figure 1-1, downstream from the respiratory
bronchioles, the alveolar ducts form more alveoli and thus, more gas exchange can take
place in these airways. Generation 23 is usually the last branch of the airway tree and these
are the alveolar sacs which are completely lined with alveoli. This is where most of the
gas exchange takes place.16 Gas exchange follows simple diffusion, as described by Fick’s
law of diffusion, outlined in Equation 1 below, where A is the area of diffusion, D is the
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diffusion coefficient of gas, P1 and P2 are the partial pressures of the gas on either side of
the alveolar membrane and finally, T is the thickness of the membrane.
𝐷𝑖𝑓𝑓𝑢𝑠𝑖𝑜𝑛 =

𝐴 ∙ 𝐷 ∙ (𝑃1 − 𝑃2 )
𝑇

(1)

Figure 1-1: Human airway tree. This diagram is not drawn to scale. The first 16
generations represent the conducting zone while generations 17-23 represent the
respiratory zone of the airways. Image adapted from West JB, Respiratory Physiology; The
Essentials16
Diffusion of oxygen across the alveolar membrane occurs from an area with high partial
pressure inside the alveoli to low partial pressure in the pulmonary capillaries.16 Since the
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alveolar membrane is very thin and has a large area between 50 and 100 square meters, it
is very well suited for efficient diffusion to occur.16 Since respiratory airways do not have
a mucociliary escalator like conductive airways, macrophages remove waste and particles
by carrying them either to the mucociliary escalator or into the bloodstream.15

Established methods for measuring lung function
Several techniques have emerged to assess the function of the lung. Pulmonary function
tests provide a quantitative evaluation of global lung function and include spirometry,
plethysmography and diffusing capacity of carbon monoxide (DLCO).19 The six-minute
walk distance (6MWD)20 test provides a means of evaluating exercise capacity and
breathlessness. Qualitative measures of lung function include the modified Medical
Research Council (mMRC) dyspnea scale21 as well as the St. George’s Respiratory
Questionnaire (SGRQ).22, 23 These tests are relatively inexpensive making them widely
available and useful tools in the clinical setting as well as in research. In the following
sections, I will describe these tests in more detail.

1.4.1

Pulmonary function tests

Pulmonary function tests provide global measurements of the overall function of the lung.
Spirometry, which is the most common test and most widely seen in the clinic, measures
dynamic flow rates using a spirometer (Figure 1-2A) and is the current gold standard for
measuring lung function. During a spirometry test, the subject is first instructed to take a
deep breath all the way in and then is asked to blast the air out as hard and as fast as
possible, all the way out, through the mouthpiece of the instrument. This maneuver
provides us with two parameters, the forced expiratory volume in one second (FEV1),
which is the amount of air that can be forcefully exhaled in the first second of the maneuver,
and the forced vital capacity (FVC), which is the total amount of air that can be exhaled
from the lungs, as shown in Figure 1-2B. The patient then returns to normal breathing.
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A

B

Figure 1-2: Spirometry measurement. Panel A shows an EasyOne hand-held spirometer.
To perform a measurement, the subject takes a deep breath all the way in, then is asked to
blast the air as fast and hard as possible all the way out through the mouthpiece. Panel B
shows the airflow curve for this maneuver with the forced expiratory volume in one second
and forced vital capacity overlaid.

A plethysmograph, shown in Figure 1-3A, is an instrument which provides a closed system
environment that measures pressure differences and utilizes Boyle’s law, to calculate static
lung volumes. Boyle’s law is shown in Equation 2, where Pl and Vl are the pressure and
the volume of gas in the lung respectively, while Pb and Vb are the pressure and volume in
the box.
𝑃𝑙 𝑉𝑙 = 𝑃𝑏 𝑉𝑏

(2)

Volumes that can be obtained using plethysmography are total lung capacity (TLC), the
total amount of air that is present in the lungs after maximum inhalation; tidal volume (TV),
the amount of air inhaled and exhaled during regular breathing at rest; functional residual
capacity (FRC), the amount of air present in the lungs at the end of a normal breath at rest;
expiratory reserve volume (ERV), the volume of air that can be exhaled after completing a
regular exhalation at rest; residual volume (RV), the amount of air that remains in the lungs
after maximal exhalation; inspiratory reserve volume (IRV), the maximum amount of gas
that can be inhaled after completing a normal inhalation at rest; vital capacity (VC), the
total amount of air that can be exhaled after the deepest inspiration; inspiratory capacity
(IC), the total amount of air that can be inhaled after a normal exhalation at rest. To obtain
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these volumes, shown in Figure 1-3B, subjects are instructed to start with normal breathing
while seated in the closed system. When they reach FRC a shutter closes, blocking the
flow of air from entering and exiting the lungs. As the subject attempts to breathe against
the shutter, the pressure in the lungs decreases and the volume increases causing the
pressure in the box to increase and the volume to decrease. Boyle’s law is then used to
find the volume of air in the lungs.

A

B

Figure 1-3: Static lung volumes. Panel A shows the body plethysmograph that is used in
our laboratory. This device is used to measure static lung volumes shown in panel B based
on Boyle’s law. Panel B adapted from Respiratory Physiology.24
To measure gas exchange across the alveolar membrane, a third test which measures the
diffusing capacity of carbon monoxide (DLCO) can be used. During this maneuver, the
subject is instructed to start with normal breathing. After a few normal breaths, the subject
is instructed to blow all the way out until RV is reached, and then to breath in quickly.
During the quick inspiration, the subject inhales a gas mixture with a low known
concentration of carbon monoxide mixed with tracer gas, generally helium, and air. After
a ten second breath hold the subject breathes out and the exhaled gas mixture is analyzed.
Gas exchange is then calculated based on the difference in concentrations between the
inhaled gases and alveolar gas sample.19 All of the previously introduced measurements

9

of dynamic flow rates, static lung volumes and gas exchange are often expressed as a
percent predicted value (%pred) which is calculated based on the gender, age, height and
ethnicity of the individual being tested.3, 25

1.4.2

Six-minute walk distance

The six-minute walk distance (6MWD) is a test to assess exercise capacity according to
guidelines set by the American Thoracic Society.20 During this test the subject is asked to
perform walking for six continuous minutes at a normal, comfortable pace along a flat
corridor with a hard surface.20 The Borg scale26 is used to rate the breathlessness and
overall physical fatigue before and after the test. Oxygen saturation (SpO2) and heart rate
are often recorded before and after the 6MWD test even though they are not a mandatory
component. Previous studies have shown that 6MWD outcomes correlate well with
morbidity and mortality.27, 28

1.4.3

Evaluating dyspnea and quality of life

As previously introduced, the mMRC21 questionnaire has been developed to assess the
level of dyspnea of an individual. The questionnaire ranks dyspnea on a level of Grade 0
(“I only get breathless with strenuous exercise”) to Grade 4 (“I am too breathless to leave
the house or I am breathless when dressing or undressing”).21, 29 Previous work has shown
that the mMRC correlates well with 5-year mortality rates.30 The SGRQ22, 23 is another
qualitative questionnaire developed for assessing overall quality of life in patients with
obstructive airways disease. It evaluates symptoms, activities that relate to breathlessness
and disturbance of daily life.22 Each of the three topics are given a score ranging between
zero and one hundred where a high score reflects a poor quality of life.22

COPD and Acute Exacerbations
1.5.1

Normal aging of the lung and COPD

As individuals age, like any other organ, the lung undergoes several important
physiological changes. Previous work has shown that over time, there is a decrease in the
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elastic recoil of the lung, a decrease in the compliance of the chest wall and a decrease in
the strength of the respiratory muscle.31

Furthermore, it has also been shown that

individuals over 60 years of age can experience “senile emphysema”, the homogeneous
enlargement of airspaces without alveolar destruction or chronic inflammation.32
Individuals with chronic obstructive pulmonary disease (COPD) experience an accelerated
loss of lung function. As previously described COPD primarily affects our elderly
population who have been exposed to tobacco smoke for extended periods of time.3, 33
COPD is an inflammatory disease which can be broken down into two main conditions
known as airways disease and emphysema. During airways disease, the walls of the
airways are inflamed34 and become thickened. Mucus secretion is increased, plugging the
airways and leading to airway obstruction.35, 36 During emphysema, the inflammatory
response in the lung parenchyma causes destruction of lung tissue leading to alveolar
enlargement.36, 37 The current definition of emphysema set by the National Heart, Lung
and Blood Institute states that emphysema is “a condition of the lung characterized by
abnormal, permanent enlargement of airspaces distal to the terminal bronchiole,
accompanied by the destruction of their walls and without obvious fibrosis”.38 Emphysema
and airways disease are two separate conditions in COPD which can occur on their own or
can coexist and the extent of each can vary amongst individuals. To diagnose COPD,
spirometry is used where a post bronchodilator FEV1/FVC < 70% indicates disease and
disease severity is determined by the FEV1%pred score as outlined in Table 1-2.
Table 1-2 Spirometric classification of COPD
Stage
Severity
GOLD 1:
mild
GOLD 2:
moderate
GOLD 3:
severe
GOLD 4:
very severe
Adapted from Vestbo et al.39

1.5.2

FEV1 Criteria
FEV1 ≥ 80%pred
50%pred ≤ FEV1 < 80%pred
30%pred ≤ FEV1 < 50%pred
FEV1 < 30%pred

Acute exacerbations

As discussed above, COPD exacerbations are often experienced by individuals who are in
moderate to severe stages of the disease. Guidelines set by the World Health Organization
(WHO) and US National Heart Lung and Blood Institute Global Initiative for Chronic

11

Obstructive Lung disease (GOLD)3 define a COPD exacerbations as: ‘‘an event in the
natural course of the disease characterized by a change in the patient’s baseline dyspnea,
cough, and/or sputum that is beyond normal day-to-day variations, is acute in onset, and
may warrant a change in regular medication in a patient with underlying COPD”. 3 It has
been previously shown that the frequency of exacerbations increases with the severity of
COPD. Frequency of exacerbations is an independent determinant of health-related patient
quality of life.40, 41 It has also been shown that exacerbations are associated with an
increase in inflammatory markers that lead to accelerated disease progression.42, 43 It is
now believed that exacerbations are primarily triggered by viral and/or bacterial infections
as well as air pollution.44-47 Individuals are more prone to viral infections through the
winter months and these types of infections tend to have longer recovery times than
bacterial infections or those caused by air pollution.48, 49 Current treatment for exacerbation
depends on the severity of the event and is generally based on the clinical presentation of
the patient.50 Treatment includes use of short-acting β2-agonist (such as salbutamol) and/or
ipratropium MDI bronchodilators, corticosteroids such as prednisone, and antibiotics.50-52
A previous study by Seemungal et al.53 has shown that the median time for recovery from
exacerbation symptoms is 7 (4 to 14) days; however there are a significant number of cases
where full recovery to baseline values are not reached.53 A different study demonstrated
that patients who seek treatment sooner experience a faster recovery and report a higher
health-related quality of life than those patients with more untreated exacerbations.54
Evidence shows that about 50% of the exacerbations remain unreported4, 40 which increases
the risk for requiring an emergency hospitalization.54 Aside from a decreased quality of
life and increased morbidity of COPD patients, exacerbations also place a huge burden on
the healthcare system.

In Canada, the total cost for treating moderate and severe

exacerbations including outpatient treatment, emergency department visits and
hospitalization services is estimated to range from $646 to $736 million per year.55 This
amount is primarily attributed to hospitalizations which on average lasted 10 days and cost
$8669 per individual.55 A different study reported similar findings where the median
hospital stay was reported to be 9 (5 to 15) days with a median cost of $7100 ($4100 to
$16000) per individual.56

Costs associated with treating moderate and severe

exacerbations in the outpatient setting and emergency room are also significant and should
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be considered.

Treatment of moderate exacerbations in the outpatient setting and

emergency room on average cost $126 and $515 per visit respectively.55 Similarly, severe
exacerbations cost $114 and $774 to treat in the outpatient setting and emergency room
respectively.55 Figure 1-4 outlines the cost breakdown for treating acute exacerbations,
and as expected, hospitalizations account for the largest proportion of total cost57.

M e d ic a tio n 3 2 %
C lin ic v is it 5 .6 %
E m e r g e n c y 4 .4 %
H o s p ita liz a tio n 5 8 % 5 8 %

Figure 1-4: Exacerbation cost breakdown. This pie graph shows the costs attributed to
treating COPD exacerbations. As expected, hospitalizations account for the largest
proportion of total cost. Image adapted from Chapman et al57

Although frequency of exacerbations was shown to be related to a long-term decline in
lung function58, there are currently no widely available biomarkers able to predict the
occurrence of these events. It has recently been shown that the single best predictor of
acute exacerbations was the occurrence of previous exacerbations.59 Therefore, there is
need for new techniques that are able to predict the occurrence of these events for early
detection and prevention of these episodes, as it would greatly improve patient quality of
life, slow disease progression and decrease hospital costs associated with treatment.
Decreasing costs attributed to hospitalization alone could halve the current costs required
for treating COPD exacerbations.
Several studies have investigated preventive drugs that could potentially improve patient
outcomes and reduce the number of hospitalizations. It has been shown that influenza
vaccinations and treatment with immunostimulants may lower the number of exacerbations
and are now recommended for individuals with COPD of significant severity.44, 60-63 Long
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acting bronchodilators (long-acting beta 2 agonist) such as salmeterol were shown to
reduce the number of exacerbations over a 3-year period.64 Pulmonary rehabilitation and
self-management are also believed to reduce exacerbation risk. Evidence shows that
exercise training can reduce the length of hospital stays following an exacerbation54 and
reduce the risk of being re-admitted.65 Finally, long term oxygen therapy has also been
shown to reduce the number of hospital admissions, in particular in hypoxaemic COPD
individuals.66

Imaging Lung Function and Structure
1.6.1

X-ray Computed Tomography

Plane X-rays were introduced in 1895 as an important imaging modality. However, the
projection nature of these images limits their use.67 Computed tomography (CT) utilizes
X-rays to form two dimensional cross-sectional images of the body.67 While Nobel Prize
recipients G.N. Hounsfield and A.M. Cormack introduced the clinical significance of CT
in 1972, much of this work relied on theoretical work by J.H. Radon in 1917 and Bernard
Ziedses des Plantes in 1931.67 The first CT scanner was intended for imaging of the brain,
but its use was later extended to many different applications with the development of the
whole body CT scanner in 1975. CT imaging utilizes X-ray transmission profiles captured
under a number of different angles through cross sections of the body.67 To capture
multiple transmission profiles, an X-ray source and detectors are mounted on a gantry
which rotates around the patient.67 First generation CT scanners acquired multiple X-ray
profiles for each cross sectional image by rotating 360 degrees around the patient.67 Then
the patient would be shifted a short distance by moving the table so that the next slice could
be captured.67

The rotation of the gantry was limited by wires attached to the

instrumentation on the gantry. Modern CT scanners have an improved design, such that
the gantry can rotate an unlimited number of times in the same direction. With this
improvement, spiral CT was developed where the patient is translated through the bore of
the gantry while transmission profiles are captured.67 Modern CT scanners also utilize
multi-slice detectors along with a fan shaped X-ray beam, allowing for multiple
transmission profiles to be recorded simultaneously, significantly decreasing acquisition
time and allowing for whole body imaging within a single breath-hold.67 The CT scanner
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used to capture images for our studies consists of a 64 slice array of detectors. Panel A of
Figure 1-5 represents the acquisition pattern of a spiral acquisition, while panel B
demonstrates the multi-slice aspect of the acquisition.

Figure 1-5: CT acquisition. The subject is translated through the bore of the gantry while
the X-ray source and the detectors attached to the gantry rotate freely around the subject.
Panel A shows the spiral acquisition resulting from this process. Panel B depicts the
concept of a fan shaped X-ray beam and detectors spanning multiple slices. Image adapted
from Castellano et al.67

Images are reconstructed by intensive mathematical computations, known as filtered back
projections, of the measured transmission profiles.68

The pixel intensities in the

reconstructed image are determined based on the corresponding linear attenuation
coefficients of tissues (µtissue) in the body and are measured in Hounsfield units (HU). As
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shown in Equation 3, Hounsfield values are normalized to the linear attenuation coefficient
of water, thus water has a value of 0HU. By definition, air is -1000HU, lung is from 600HU to -950HU, fat is from -60HU to -80HU, soft tissue is from 20HU to 70HU and
bone is 1000HU or higher.

𝐻𝑈 =

𝜇𝑡𝑖𝑠𝑠𝑢𝑒 −𝜇𝑤𝑎𝑡𝑒𝑟
𝜇𝑤𝑎𝑡𝑒𝑟

× 1000

(3)

Important parameters that are considered when acquiring an image are the rotation time,
which is the amount of time taken by the gantry to complete a single revolution; the tube
voltage; the tube current, which is generally limited by overheating of the X-ray tube and
the scan time; and, the pitch, which is the ratio of table translation per 360 degrees of tube
rotation relative to the beam width. All of these factors are optimized such that images of
sufficient diagnostic quality are achieved while limiting the ionizing radiation that the
patient is exposed to.
Computed tomography is the imaging method of choice for lung imaging as it allows for
the visualization of airways and parenchyma.69-72 Emphysematous lesions in the lung
parenchyma have lower tissue densities than healthy lung tissue and can be identified by
regions of lower attenuation values, in Hounsfield units, on density frequency
histograms.71, 73 The extent of emphysema can be evaluated using a thresh-hold cut-off
value; the voxels below this value are characterized as emphysematous tissue.

A

commonly used cut-off is -950 HU, where tissues with attenuation values below -950 HU
are characterized as emphysema.74
Airway remodeling in COPD is primarily caused by inflammation in the epithelium of the
airway wall and mucus plugs in the airway lumen.36 Therefore, airways disease severity
can also be evaluated using computed tomography by obtaining dimensions of the airway
wall area and lumen area.75 These measurements are challenging since airway
inflammation primarily affects the small airways (<2mm in diameter)35, which are difficult
to visualize using CT.73, 76
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1.6.2

Magnetic resonance imaging

Conventional proton magnetic resonance imaging (1H MRI) has become a widely used
medical imaging modality which relies on the presence of water- and fat- bound hydrogen
(1H) atoms in the body to acquire images.77 However, due to the relatively low 1H density
present in the lungs, as shown in Figure 1-6A, the thoracic cavity appears black on
conventional 1H images, providing little morphological information about the lungs.77 This
limitation has triggered the development of new MRI techniques for visualizing lung
function and structure. In particular, the development of hyperpolarized noble gas imaging
has emerged as a useful technique for imaging the lungs.73, 78 Breath-hold imaging after
inhalation of hyperpolarized helium-3 (3He) allows for visualization of gas distribution
within the lungs.77 These images are known as static ventilation images and examples are
shown in Figures 1-6B and C. Figure 1-6B represents a healthy adult where after inhalation
of 3He the signal is homogeneously distributed throughout the lungs. A homogeneous
signal distribution suggests that all areas of the lung have a homogeneous gas distribution.

Figure 1-6: Proton and hyperpolarized helium-3 MRI of lung. Panel A shows proton
image of lungs. Panel B shows hyperpolarized helium-3 (3He) MRI overlaid on proton
MRI for a healthy individual; the inhaled gas is homogeneously distributed in the lungs.
Panel C shows 3He MRI static ventilation image overlaid on proton MRI for an individual
with COPD. Areas of signal void in the image represent ventilation defects in the lung.

In contrast, Figure 1-6C shows the signal distribution for an individual with COPD, with
regions of signal void, known as ventilation defects. These areas are indicative of poorly
ventilated or completely unventilated regions in the lung. Quantitative measurements of
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ventilation defects have been developed, such as ventilation defect volume (VDV)79 and
ventilation defect percent (VDP)80 by normalizing static ventilation images to the thoracic
cavity volume obtain using 1H MRI. The etiology of ventilation defects is still unclear. It
is believed that in COPD they may be due to airway disease, emphysema or a combination
of both diseases.73 It is also possible that ventilation defects are slow filling regions of the
lung, relative to the breath-hold scan.
3

He MRI has also been used for evaluating the microstructure of the lungs. Diffusion

weighted 3He MRI imaging allows for characterization of alveolar size.81-83 By generating
apparent diffusion coefficient (ADC) maps, alveolar destruction in emphysema can be
quantified, where higher ADC values represent larger alveolar spaces and therefore greater
disease severity.82 Higher ADC values are generated for diseased individuals, because the
gas atoms travel further per unit time.73 Figure 1-7 depicts ADC maps for a healthy subject
and an individual with COPD where the severity of disease is represented by brighter
colours.

Figure 1-7: Apparent diffusion coefficient (ADC) maps. Left panel represents a healthy
individual while right panel represents an individual with emphysema. Brighter colour
represents higher ADC values.
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The Pulmonary Arteries
The cardiovascular system can be divided into two components, the systemic circulation
which includes blood delivery between the heart and the organs and tissues in the body,
and the pulmonary circulation which includes blood delivery between the heart and the
lungs for re-oxygenation and waste removal.84 The pulmonary arteries (PA) make up the
first component of the pulmonary circulation. They are responsible for delivering oxygenpoor blood from the right ventricle of the heart to the lungs so that it can become reoxygenated.85 As shown in Figure 1-8, the main pulmonary artery or the pulmonary trunk,
leads from the right ventricle of the heart and it divides into the left and right pulmonary
arteries, supplying the left and right lung respectively.

Figure 1-8: Pulmonary circulation. Black arrows represent the direction of blood flow in
the heart. De-oxygenated blood leaves the right ventricle of the heart through the main
pulmonary artery (PA). The main PA then divides into the right and left PAs which then
divide into three and two lobar arteries respectively. Arteries continue to branch along with
the airway tree. Gas exchange occurs in the pulmonary capillaries where diffusion allows
carbon dioxide (CO2) to be removed from the blood and for blood to get re-oxygenated.
Oxygenated blood returns to the heart to be transported to the systemic circulation.
Image adapted from Marieb EN, Human Anatomy.85
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Each PA then divides into lobar arteries to supply the three lobes of the right and the two
lobes of the left lung.85 The arteries continue dividing, along with the bronchi and
bronchioles in the lung, becoming arterioles, and finally pulmonary capillaries at the level
of the alveoli where most gas exchange occurs. As previously described, gas exchange
occurs as determined by Fick’s law of diffusion outlined in Equation 1.
As shown in Figure 1-9, the walls of the pulmonary arteries are assembled from three main
layers, each of which have a different composition. The layer closest to the lumen is called
the tunica intima layer and is made up of endothelial cells as well as a thin layer of
connective elastic tissue.17 The composition of the next layer, known as the tunica media,
changes as the size of the artery becomes smaller. Larger arteries have media layers made
of connective elastic tissue, while smaller vessels have media layers made up of smooth
muscle.17 The smallest arterioles in the pulmonary circulation however, do not have a
detectable smooth muscle media layer.86 The tunica adventitia is the outermost layer of
the artery and is made up of connective tissue. Smaller vessels present in this layer provide
nutrients for all three layers of the artery.17

Figure 1-9: Layers of pulmonary artery walls. The three main layers that compose the
walls of pulmonary arteries are the tunica intima, tunica media and tunica adventitia
moving from the lumen towards the outside of the vessel.
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Imaging pulmonary artery abnormalities
Cardiovascular disease is an important risk factor in individuals with COPD. Evidence
shows that it is the single largest cause of hospitalizations and the leading cause of death,
following lung cancer.9, 10 Specifically, pulmonary vascular disease has been associated
with exacerbation related hospitalizations as well as mortality.87-89 A common condition
is the enlargement of the pulmonary artery (PA) trunk and often the right ventricle of the
heart. It is believed that in order to re-direct blood-flow to well ventilated regions of the
lung, hypoxic arteriolar vasoconstriction increases the resistance of the pulmonary
vasculature, increasing the pressure in the PA trunk and in the right ventricle of the heart.90
This increase in pressure leads to an enlarged pulmonary artery and a condition known as
pulmonary hypertension (PH).90 Currently the gold standard for monitoring PH is through
right heart catheterization; however, this is an invasive technique and can cause
discomfort.11 The invasiveness of this technique makes it unsuitable for performing
repeated measurements and therefore unsuitable for evaluating disease progression and
treatment response.

Therefore, several studies have sought to estimate pulmonary

hypertension by evaluating pulmonary artery abnormalities using non-invasive imaging
techniques. In the following subsections I will discuss different imaging modalities that
have been considered for evaluating the size of the pulmonary artery.

1.8.1

Imaging PA using Doppler echocardiography

Doppler echocardiography is the most common imaging technique for evaluating
individuals at risk of pulmonary hypertension.91 This non-invasive technique measures the
peak velocity of the regurgitant jet through the tricuspid valves.91 However, numerous
studies have explored the relationship between echocardiography and pulmonary artery
pressures measured using right heart catheterization and have reported poor correlations
between these techniques.91-94 Therefore, right heart catheterization remains the gold
standard for evaluating pulmonary hypertension and different imaging approaches have
been proposed.
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1.8.2

Imaging PA using plane X-rays

Pulmonary artery enlargement was first evaluated on X-ray images95-98; however, this
technique was limited in predicting PH due to the projection nature of plane radiographs.99
Therefore, these studies relied on measuring the width of the right pulmonary artery to
evaluate its size as it is situated lateral to the right lower lobe bronchus and is generally
well distinguished on radiographs.100 However, in cases where the heart is dilated beyond
the right lower lobe bronchus, the right pulmonary artery is no longer well visible on plane
radiographs and is more difficult to evaluate.100

Teichmann et al. measured right

pulmonary artery diameters in 112 healthy individuals as well as 95 men suffering from
chronic bronchitis.96 They showed that PH could be diagnosed using the width of the right
pulmonary artery with a reliability of 72.2% in readable films, which dropped to 64.2%
when including films which were not reliably readable.96

The limitation of plane

radiographs triggered further research in measuring PA size with the development of x-ray
computed tomography.

1.8.3

Imaging PA using X-ray computed tomography

The limitation of plane X-ray radiographs was overcome by the discovery of X-ray
computed tomography. With advances in CT imaging, several studies have revisited the
relationship between PA size and pulmonary hypertension to determine whether it would
provide a suitable non-invasive means of assessing patients at risk. These studies have
reported a positive correlation between main pulmonary artery diameter and pulmonary
artery pressure measured using right heart catheterization.11, 99, 101-105 In particular, Lange
et al. demonstrated that the diameter of the main pulmonary artery measured on chest CT
images could potentially be used as a biomarker for predicting borderline pulmonary
hypertension.11 Furthermore, recent findings by Wells et al. suggested that a PA to aorta
(A) diameter ratio of greater than 1 (PA/A > 1), as measured on chest CT images, was
significantly associated with a history of acute exacerbations, as well as with risk factors
of future exacerbations.1 Figure 1-10 shows a representative measurement of the main
pulmonary artery (MPA) and aorta diameter.
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Figure 1-10: Pulmonary artery diameter measurement. Main pulmonary artery (MPA)
and aorta diameter measurement at the level of the bifurcation. Adapted from Wells et al.1

1.8.4

Evaluating PA abnormalities with magnetic resonance imaging

Several non-invasive, magnetic resonance imaging (MRI) techniques have been developed
to estimate pulmonary hypertension, including evaluation of pulmonary artery size.106-110
Frank et al. found significantly greater main pulmonary artery diameters measured on MRI
images in 23 hypertensive individuals when compared to a control group (n = 8).106
Furthermore, Saba et al. showed that the ventricular mass index (ratio of right ventricular
mass over left ventricular mass) was associated with pulmonary artery pressures measured
by right heart catheterization.107 Additionally, Tardivon et al. found that in a group of 13
pulmonary hypertensive individuals, acceleration time (the time from the onset of forward
flow to the moment of maximum flow velocity in the main pulmonary artery) was strongly
correlated with pulmonary artery pressure measured using right heart catheterization.108
Similar results were found by Wacker et al. in a group of 12 hypertensive patients.109
Finally, Marcus et al. showed a correlation between systolic pulmonary artery pressure and
acceleration time/ejection time ratio in a group of 12 patients.110
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Emerging tools for quantifying pulmonary artery size
As previously described, current methods for quantifying the size of the pulmonary artery
rely on a simple one-dimensional diameter measurement of the main PA to assess
morphological changes of the PA. However a one-dimensional measurement may not be
sufficient to fully encompass three-dimensional changes of the vessel.

Therefore

additional research is required to develop more accurate techniques for quantifying the size
of the PA that would encompass changes of the artery in three dimensions. Chapter two
of this thesis describes a three-dimensional method that we developed for quantifying the
size of the pulmonary artery from thoracic computed tomography images. It consists of a
slice-by-slice manual segmentation of each of the main, left and right pulmonary arteries
in planes perpendicular to the axis of each vessel.

Research Hypothesis and Objectives
As previously described, acute exacerbations of COPD are of major concern because they
reduce patients’ health-related quality of life and increase patients’ morbidity and
mortality. They also account for a large portion of healthcare costs, placing a large burden
on our healthcare system. Currently there are no widely available biomarkers that are able
to accurately predict the occurrence of these events. Previous work1 investigated the use
of a one-dimensional diameter measurement of the main pulmonary artery to evaluate
patients’ exacerbation risk. However, we believe that a three-dimensional approach would
be more appropriate for quantifying morphological changes in the pulmonary artery as it
would account for changes in all three Cartesian planes of the vessel. Therefore, the
primary objectives of this thesis were: 1) to develop a three-dimensional measurement for
assessing the size of the pulmonary artery and test the observer reproducibility and 2) to
assess the association between pulmonary artery volume and COPD, as well as
exacerbation frequency. The purpose of these objectives was to develop a quick and easyto-use biomarker that could help improve health-related patient quality of life and reduce
hospital costs.
In Chapter 2, our objective was to develop a three-dimensional volumetric measurement
technique to quantify the size of the main, left and right pulmonary arteries at the level of
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their bifurcation. Three observers performed five rounds of repeated measurements to
evaluate reproducibility. We hypothesized that measurements will be reproducible with
low inter- and intra-observer variability as well as with low longitudinal variability.
In Chapter 3, we investigated the relationship between pulmonary artery volume
measurements and measurements of lung function and structure in a group of ex-smokers.
Pulmonary artery volumes of these individuals were also compared to those measured in a
group of never-smokers. We also investigated the potential use of our technique as a
suitable biomarker for predicting the occurrence of severe exacerbations of COPD. We
hypothesized that pulmonary artery volumes will be associated with measurements of lung
function and structure. Furthermore, we hypothesized that pulmonary artery volumes will
be able to predict the occurrence of COPD exacerbations.
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CHAPTER 2: THREE-DIMENSIONAL SEGMENTATION OF
PULMONARY ARTERY VOLUME FROM THORACIC COMPUTED
TOMOGRAPHY IMAGING
This chapter describes the development of a three-dimensional volumetric measurement
for evaluating the size of the main, left and right pulmonary arteries as well as calculating
total pulmonary artery volume. The reproducibility of the volumetric measurements is also
reported in this chapter.
The contents presented here has been adapted from work previously published in the SPIE
Medical Imaging Conference Proceedings, Orlando, Florida, United States 2015, and is
reproduced here with permission provided in Appendix B.
TJ Lindenmaier, K Sheikh, E Bluemke, I Gyacskov, M Mura, C Licskai, L Mielniczuk, A
Fenster, IA Cunningham and G Parraga, Three-Dimensional Segmentation of Pulmonary
Artery Volume from Thoracic Computed Tomography Imaging. SPIE Medical Imaging,
Renaissance Orlando at SeaWorld, Orlando, Florida, United States, February 21-26, 2015

Introduction
Chronic obstructive pulmonary disease (COPD) affects the airways and the lung
parenchyma.1 It is currently the fourth leading cause of death in the United States and is
predicted to be the third leading cause of death worldwide by 2020.2

COPD is a

heterogeneous disease with various clinical phenotypes, including chronic bronchitis,
emphysema, asthma with fixed airflow obstruction, frequent exacerbation phenotype, and
COPD associated with pulmonary hypertension. There is an expanding body of literature
seeking to define COPD phenotypes and identify predictive biomarkers. The diagnosis of
COPD is confirmed using spirometry measurements of the forced expiratory volume in
one second (FEV1) and forced vital capacity (FVC). While spirometry is a diagnostic
prerequisite, it is insensitive to subclinical changes in lung function, correlates poorly with
clinical symptoms including cardiovascular disease, is a poor predictor of mortality and
does not accurately predict exacerbation frequency.3, 4 In addition to airflow limitation,
COPD is also associated with cardiovascular disease and abnormalities of the pulmonary
vasculature. For example, COPD patients commonly develop pulmonary hypertension
(PH) leading to increased morbidity and mortality.5 Previous work has shown that PH is
associated with acute exacerbations of COPD and sudden worsening of symptoms resulting
in hospitalization.6,

7

Patients with COPD frequently develop other cardiovascular

abnormalities such as carotid atherosclerosis8-13, coronary artery calcification14-17 and
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vascular dysfunction.7, 18-20 These findings cannot be explained by smoking history alone,
further emphasizing the need for new biomarkers that can predict disease development and
severity.
Recent results from the Evaluation of COPD Longitudinally to Identify Predictive
Surrogate Endpoints (ECLIPSE) study21 suggested that a history of acute exacerbations of
COPD was the single best predictor of future events. This finding strengthens the need for
biomarkers that can predict subclinical changes in lung function, disease development and
severity. Previous studies quantified the size of the pulmonary artery (PA) in order to
evaluate pulmonary vasculature abnormalities as a potential predictor of COPD
exacerbations. Typically, the aorta (A) and pulmonary artery (PA) are quantified using
manual diameter measurements at the level of the PA bifurcation in thoracic computed
tomography (CT) images.7 It was recently shown in the COPDGene cohort (N=3464) that
a PA/A ratio >1 was associated with acute exacerbations and the risk of future
exacerbations.7 Moreover, a different study showed that an increase in PA diameter was
associated with subclinical PH.22 Both of these studies utilized manual one-dimensional
measurements of the pulmonary artery. To enhance sensitivity and improve observer
variability, we aimed to develop a three-dimensional (3D) measurement of the PA from
thoracic CT. We hypothesized that 3D volumetric measurements would have an intraobserver variability <10% and high inter-observer agreement ICC > 0.90. The 3D method
is more time consuming and laborious and validation is required before a more automated
approach is considered.

Therefore, our objective was to develop and test the

reproducibility of 3D manual volumetric PA measurement from thoracic CT images.
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Methods
2.2.1

Study Subjects

All subjects provided written informed consent to a protocol that was approved by the local
research ethics board (#15930) and Health Canada. A total of 15 ex-smokers aged 56-79
(mean age: 67±7 years) with a smoking history > 10 pack-years were randomly chosen
from a cohort of 199 subjects. Three subjects were randomly selected from each of the
following four groups based on COPD disease severity using the Global Initiative for
Chronic Obstructive Lung Disease (GOLD) classification: GOLD IV (FEV1 <30%),
GOLD III (FEV1 30-49%), GOLD II (FEV1 50-79%), GOLD I (FEV1 ≥ 80%) and a fifth
group without airflow limitation (FEV1/FVC ≥ 0.70).

2.2.2

Imaging

CT images were acquired on a 64-slice Lightspeed VCT scanner (General Electric Health
Care, Milwaukee, WI USA) (64 × 0.625mm collimation, 120 kVp, 100 effective mA, tube
rotation time = 500ms, pitch=1.0).23 Subjects were first coached through normal breathing.
Once at functional residual capacity (FRC), subjects were instructed to inhale 1L of
medical grade nitrogen gas (N2) from a Tedlar® bag (Jansen Inert Products, Coral Springs,
FL, USA)23 to match lung volumes acquired using MRI. Imaging was performed using a
spiral acquisition and reconstructed using a standard convolution kernel to 1.25mm.23 The
effective dose for an average adult was estimated at 1.8mSv using the ImPACT CT patient
dosimetry calculator based on the Health Protection Agency (UK) NRPB-SR250.24
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2.2.3

PA Segmentation: Development and Application

Reconstructed CT images were evaluated in Digital Imaging and Communications in
Medicine (DICOM) format using custom-built software (3D Quantify V4.1.1, Robarts
Research Institute, London, Canada) previously developed for carotid ultrasound
measurements.25 The algorithm pipeline is summarized in Figure 2-1.

Figure 2-1: PA Volume measurement algorithm pipeline.
After setting the optimal window and level, such that the PA was well distinguished from
the surrounding tissue, the observer navigated the CT volume, shown in the top left of
Figure 2-2, to the plane where the bifurcation of the main pulmonary artery (MPA) into the
left and right pulmonary arteries (LPA and RPA respectively) was clear, as shown in the
middle left panel of Figure 2-2.
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Figure 2-2: User input for PA measurement. The user first adjusted the window and
level such that the PA was well distinguished from surroundings. The arterial bifurcation
(BF) was identified and used as a landmark for manual placement of axes a1, a2, a3 from
the BF that were parallel to the MPA, LPA and RPA respectively. The cross sectional
areas in planes perpendicular to each axis of segmentation were manually traced in 25
slices for MPA and 20 slices for LPA and RPA (only 3 representative slices shown here)
with inter-slice distance of 1.00 mm. The resulting volume was generated as shown in
Equation 4. Voxels enclosed by each polygonal surface were extracted and their union was
taken to account for the overlap between segmented vessels. The number of resulting
voxels were then multiplied by the voxel dimensions to calculate TPAV. Bottom right
panel shows a representative slice for the union of extracted voxels.

The user then set the bifurcation point (BF), and manually identified the first axis (a1) of
segmentation from the BF parallel to the MPA. The cross-sectional area of the vessel was
then manually segmented in 25 consecutive two-dimensional planes perpendicular to the
axis of segmentation, starting at the BF, with an inter-slice distance (ISD) of 1.00 mm.
This approach was repeated for the LPA and RPA (axes of segmentation a2 and a3
respectively) for 20 consecutive perpendicular planes, starting from the BF. Once the
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vessels were traced, sub-volumes were generated by multiplying each area by half the ISD
on either side of the segmented region, as shown in Figure 2-3, represented by dashed lines.

Figure 2-3: PA volume generation. Sub-volumes were generated by multiplying the area
of segmented contours by half the inter-slice distance (ISD) on either side of the contour,
represented by dashed lines above. To generate volume measurements, sub-volumes were
summed as shown in Equation 4.
𝑉=

1
2

(𝐴1 + 𝐴𝑛 ) + ∑𝑛−1
𝑖=2 𝐴𝑖

(4)

The general equation for calculating volumes in millimeters cubed is expressed as shown
in Equation 4. Volumes of the MPA, LPA and RPA were also obtained from generated
polygonal surfaces in order to calculate a total PA volume (TPAV) for the pulmonary
artery. Polygonal surfaces were generated as previously described26 for segmentation of
the carotid artery. To generate TPAV, the union of voxels enclosed by each of the MPA,
LPA and RPA was taken and multiplied by the voxel dimensions. Taking the union of
voxels, accounted for the overlap between polygonal surfaces.

Segmentation was

performed by three observers. Observer 1 (TJL) was a well-trained observer with previous
experience in CT measurements of PA as well as carotid artery segmentation from
ultrasound, while observers 2 (EB) and 3 (KS) received minimal training.

2.2.4

Evaluation and Statistical Analysis

Three observers evaluated MPA, LPA, RPA and TPA volumes for 15 ex-smokers.
Measurements were repeated five times, and in random blinded fashion with 24 hr between
measurements to reduce potential observer learning and bias. To evaluate the intraobserver variability, the coefficient of variation (CV) was generated (SD of five repeated,
independent measurements divided by the mean) for each observer.

Inter-observer

agreement was also evaluated using linear regression and intraclass correlation (ICC)
analysis. To test the long term reproducibility, observer 1 repeated measurements of the
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same 15 subjects five times and intra-class correlation analysis was performed to assess
agreement. Observer 1 also performed diameter measurements of the MPA as previously
described7 and the diameter mean over four consecutive center slices at the level of the
bifurcation was used for this estimate. IBM SPSS Statistics for Windows v21 (IBM Corp,
Armonk, NY, USA 2012) and GraphPad Prism for Windows, v6.02 (GraphPad Software,
La Jolla, CA, USA) was used for all analyses. Results were considered significant when
the probability of a type I error was less than 5% (p < .05).

Results and Discussion
2.3.1

Relationship between PA volume and PA diameter

Figure 2-4 shows the relationship for the MPA diameter and main pulmonary artery volume
(MPAV) averaged from five rounds of measurements. A second order polynomial was
used to estimate the relationship between the gold standard diameter measurements and
PA volumes and showed a strong association (r2=0.76) for PA diameter and volume. Thus,
our technique is in high agreement with the gold standard diameter measurement. Three
observers performed MPA, LPA, RPA and TPA volume measurements over five rounds
of measurements, as previously mentioned, to evaluate inter- and intra-observer variability.
50
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Figure 2-4: Relationship between PA volume and diameter. Second order polynomial
was used to evaluate the association between novel PA volume and diameter.
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2.3.2

Intra-observer variability

Figure 2-5 shows representative measurements of the same observer and different
observers overlaid to visually asses the variability between measurements. Figure 2-6
shows mean CV for each subject and observer. The pooled CV for observer 1 was:
MPA:2%, LPA:3%, RPA:2%, TPA:2%, for observer 2 was MPA:8%, LPA:5%, RPA:5%,
TPA:6%, and for observer 3 was: MPA:3%, LPA:3%, RPA:3%, TPA:3 %.

Figure 2-5: Representative measurements. Within and between observer agreements.
Top panels show measurements performed by the same observer (observer 1) on two
different subjects, high agreement on left and low agreement on right. Different colours
represent measurements performed in two separate rounds of the trial. Bottom panels show
measurements performed by three different observers (observer 1, observer 2 and observer
3), on two different subjects, with high agreement on left and low agreement on right. Red
outline was performed by observer 1 (well-trained), while blue and green outlines were
performed by observers 2 and 3 respectively (minimal training).
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Figure 2-6: Intra-observer variability. Mean CV for Observers 1-3. ID# 178, 196 were
excluded from TPA measurements for Observer 2 – Round 4 due to missing data.

2.3.3

Inter-observer variability

Figure 2-7 shows strong linear relationships for mean MPA (r2=0.96, p<.001), LPA
(r2=0.98, p<.001) RPA (r2=0.99, p<.001) and TPA (r2=0.98, p<.001) volumes from the five
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rounds of measurements for observers 1 and 2 as well as strong linear relationships for
mean MPA (r2=0.98, p<.001), LPA (r2=0.98, p<.001), RPA (r2=0.99, p<.001) and TPA
(r2=0.99, p<.001) for observers 1 and 3. ICC analysis also showed high agreement for
measurements performed by three observers (ICC MPA=0.98, ICCLPA=0.98, ICCRPA=0.99,
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Figure 2-7: Inter-observer variability. Linear relationships for mean MPA, LPA, RPA
and TPAV measurements for observer 1 (expert) with observers 2 and 3 (minimallytrained).

2.3.4

Long-term variability

To assess the long term reproducibility of our technique, observer 1 repeated five
measurement rounds four months after completing the baseline reproducibility trial. ICC
analysis revealed high agreement for baseline and follow-up measurements
(ICCMPA=0.998, ICCLPA=0.995, ICCRPA=0.998, ICCTPA=0.997).
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Conclusion
We developed a manual method to generate three-dimensional volumes at the bifurcation
for the main, left and right PA. Volumetric measurements were in agreement (r2 = 0.76)
with PA diameter measurements, which served as the gold standard. Inter-observer
variability was low with strong inter-observer correlations providing a strong rationale to
automate this measurement for clinical workflows.
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CHAPTER 3: PULMONARY ARTERY ABNORMALITIES IN EXSMOKERS WITH AND WITHOUT AIRFLOW LIMITATION
This chapter describes the relationship between pulmonary artery volume measurements,
described in Chapter 2, and measurements of lung function and structure in a group of
COPD ex-smokers and a small group of never-smokers.
The contents of this chapter are to be submitted to the Journal of Chronic Obstructive
Pulmonary Disease for peer review, April 2015.
Tamas J Lindenmaier, Miranda Kirby, Gregory Paulin, Marco Mura, Christopher Licskai,
Harvey O Coxson, Ian A Cunningham and Grace Parraga, Pulmonary Artery
Abnormalities in Ex-smokers with and without Airflow Limitation, J COPD.

Introduction
Chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death in the
United States and estimates predict that in 2020, COPD will be the third leading cause of
death worldwide.1 In COPD patients, chronic lung inflammation and tissue destruction is
the result of long-term inhalation of toxins, mainly tobacco smoke2, leading to the
accelerated loss of lung function3, reduced quality-of-life, and premature death.4 As the
disease progresses, those with moderate-to-severe disease are likely to experience acute
events known as exacerbations.5 These individuals experience a reduced quality of life
and seek immediate medical attention which often results in hospitalization, placing a large
burden on the healthcare system.
Although the hallmark feature of COPD is pulmonary airflow limitation measured using
spirometry, COPD is also associated with vascular abnormalities including coronary
vascular and cerebrovascular disease6-9 and pulmonary artery abnormalities.3 Importantly,
vascular disease is the single largest cause of hospitalization in COPD patients with mild
or moderate disease and after lung cancer, the leading cause of death.10, 11 There is also a
dose-response relationship for pulmonary structure-function abnormalities with carotid
atherosclerosis12-17, coronary artery calcification6-9 and vascular dysfunction.3, 18-20 While
this previous work showed the importance of vascular disease in COPD patients that cannot
be explained by smoking history alone12, 13, 15-17, 21, the mechanisms of vascular disease
acceleration in COPD patients are not well-established.
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We recently showed that ex-smokers with normal airflow measurements reported
significantly greater ventilation abnormalities, measured using hyperpolarized noble gas
magnetic resonance imaging (MRI), and more severe carotid atherosclerosis as compared
to never-smokers.22

This study exploited the sensitivity of three-dimensional (3D)

pulmonary MRI and carotid ultrasound and provided quantitative evidence of mild airways
disease and carotid plaque that was significantly greater in ex-smokers as compared to
never-smokers. Based on these previous findings, we sought to ascertain whether there
were also pulmonary artery abnormalities in otherwise normal ex-smokers without airflow
limitation. This is important because there is a dearth of direct evidence relating subclinical
pulmonary disease (airways disease and emphysema) with pulmonary artery abnormalities
in otherwise healthy ex-smokers. We aimed therefore to quantify any potential underlying
relationships between pulmonary airway and parenchymal abnormalities with pulmonary
artery abnormalities in mild and subclinical COPD. We also aimed to quantitatively
compare pulmonary artery morphology in normal ex- and healthy never-smokers as well
as in COPD patients. The relationship of pulmonary artery abnormalities3 and pulmonary
hypertension23-25 with lung abnormalities in COPD is well-established. In one recent
example, the relationship of pulmonary artery abnormalities with acute exacerbations of
COPD3 was shown, but the relevance of this for clinical practice was not ascertained. This
was an important results because until now there are very few quantitative biomarkers
available that help predict COPD exacerbations.3, 26
Here our objective was to measure three-dimensional pulmonary artery vessel
measurements from thoracic CT as well as pulmonary airways disease and emphysema
measurements from thoracic CT and MRI in a small group of ex-smokers and a control
group of healthy never-smokers. In the subset of patients with COPD and based on
previous findings that related 1D pulmonary artery measurements and exacerbations in the
large-scale ECLIPSE and COPDgene cohorts, we also aimed to determine the sensitivity
of 3D pulmonary artery measurements to COPD exacerbations. We hypothesized that
quantitative 3D imaging measurements of the pulmonary artery, airways and parenchyma
would reveal the direct relationships of early or subclinical pulmonary disease with
pulmonary artery abnormalities in ex-smokers.
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Methods
3.2.1

Study Participants

All research volunteers provided written informed consent to a protocol, approved by a
local research ethics board and Health Canada. We conducted retrospective analysis of a
group of ex-smokers with or without airflow limitation and healthy never-smoker subjects
which served as the control group. The inclusion criteria for COPD ex-smokers included
smoking history ≥10 pack-years, 50-85 years of age with a physician diagnosis of COPD
and post-bronchodilator forced expiratory volume in 1 second (FEV1)/forced vital capacity
(FVC) ratio <0.70, in accordance with the Global initiative for chronic Obstructive Lung
Disease (GOLD) criteria.27 Ex-smokers without airflow limitation were enrolled with the
same age-range and smoking history but with FEV1/FVC ≥0.70. Exclusion criteria
included a current diagnosis of asthma or other respiratory conditions. We did not
prospectively exclude subjects with other COPD co-morbidities. The inclusion criteria for
the healthy never-smokers was 60 to 90 years of age with a smoking history of <0.5 packyears and no history of unstable cardiovascular disease or chronic respiratory disease.
Because of the significant impact of exacerbations on COPD patient mortality28, we
recorded severe exacerbations requiring hospitalization for all patients with COPD. The
number of acute exacerbations requiring hospitalization was determined using patient
hospital records (PowerChart® Cerner Corporation, Missouri, USA) as previously
described.29 The total number of hospitalizations was defined as the total number of
hospitalizations that occurred between 2.5yr prior to and 2.5yr following the study visit
(from time -2.5 to 2.5 years). The number of prior hospitalizations was defined as the total
number of hospitalizations between 2.5yr and 5yr prior to the study visit (from time -5
to -2.5 years).

3.2.2

Spirometry, plethysmography, quality of life and exercise
capacity measurements

Spirometry and lung volumes were acquired using body plethysmography (MedGraphics
Corporation, St Paul, Minnesota, USA) following American Thoracic Society and
European Respiratory Society (ERS) guidelines;30 the attached gas analyzer
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(MedGraphics) was used to measure the diffusing capacity for carbon monoxide (DLCO).
Quality of life was assessed using the St. George’s Respiratory Questionnaire
(SGRQ)31, 32; exercise capacity was measured using a standard 6-Minute Walk Distance
Test (6MWD)33.

3.2.3

Image acquisition

MRI was performed using a 3.0 Tesla MR750 (General Electric Health Care, Milwaukee,
WI) system34 for acquisition of conventional 1H, 3He static ventilation and 3He diffusionweighted MRI. Conventional 1H MRI was acquired during 1.0L breath-hold of N2 from a
1.0 L Tedlar® bag from functional residual capacity (FRC). Prior to 3He static ventilation
and 3He diffusion-weighted MRI, a spin-exchange polarizer system (Polarean, Durham,
NC, USA) was used to polarize 3He gas to 30-40%. 3He static ventilation and diffusionweighted imaging were performed following inhalation of a 3He/N2 gas mixture (3He dose
= 5 ml/kg body weight) from a 1.0 L Tedlar® bag from FRC as previously described.34
Multi-detector CT was performed using the 64-slice Lightspeed VCT system (GEHC,
Milwaukee, WI USA) with participants in breath-hold after inhalation of 1.0L of N2 from
FRC35 in order to match the MRI lung volume. The ECLIPSE imaging protocol36 was
adapted and used: 64x0.625mm collimation, 120kVp, 100 effective mA, 500ms tube
rotation time, pitch of 1.00 and image reconstruction using a standard convolution kernel
to 1.25mm. We calculated radiation dose according to our manufacturer settings using the
ImPACT CT patient dosimetry calculator based on the Health Protection Agency (UK)
NRPB-SR250 and the total effective dose for an average adult was 1.8 mSv.37

3.2.4

Image analysis

All MRI and CT analyses were performed by an expert in quantitative imaging analysis
(M.K) with five years of experience developing and performing semi-automated 3He MRI
segmentation using custom-built software generated using MATLAB R2007b (The Mathworks Inc., Massachusetts, USA). The inter- and intra-reproducibility of the 3He MRI
segmentation software was previously evaluated in subjects with COPD38 and therefore
MR images were evaluated once by a single expert observer. 3He MRI ventilation defect
percent (VDP) was quantified by registering the 3He static ventilation images to the 1H MR
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images in order to delineate the defect boundary as previously described.39 3He apparent
diffusion coefficient (ADC) maps were also generated from 3He diffusion-weighted images
as previously described.40
Pulmonary CT measurements were generated using Pulmonary Workstation 2.0 (VIDA
Diagnostics, Inc., Coralville, IA) including airway wall area (WA) and lumen area (LA)
for 5th generation airways41, the relative area of the CT density histogram with attenuation
values < −950 HU (RA950)42, and low attenuation clusters (LAC) of connected regions with
CT densitometry values < -950 HU.43
For volumetric analysis of the pulmonary arteries, DICOM (Digital Imaging and
Communications in Medicine) thoracic CT images were evaluated using custom-built
software (3D Quantify V4.1.1, Robarts Research Institute, London, Canada), originally
developed for three-dimensional visualization and quantification of carotid ultrasound
volumes.44 The main pulmonary artery volume, left pulmonary artery volume and right
pulmonary artery volume were generated, as previously described.45 As shown in Figure
3-1, the bifurcation of the main pulmonary artery was identified as the branch-point
between the left and right pulmonary arteries. As previously described45, the axes of
segmentation were established from the bifurcation (BF) parallel to each of the main, left
and right pulmonary arteries. The artery wall boundary was manually segmented in planes
perpendicular to the axes of segmentation for 25 x 1mm slices for the main and 20 x 1mm
slices for the left and right pulmonary arteries. Based on the segmented areas and the interslice distance, a volume for the segmented region of the vessel was generated. Total
pulmonary artery volume was also generated as previously described.45 To account for
overlapping regions between main, left and right pulmonary artery volume measurements,
the union of voxels enclosed by each boundary was taken and multiplied by the voxel
dimensions. We previously reported low inter- and intra-observer variability for pulmonary
artery volumetric measurements and therefore measurements were performed by a single
observer (T.J.L).45 To account for gender differences in pulmonary artery volumes,
measurements were normalized by body surface area and age.
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It was previously shown that the pulmonary artery to aorta diameter ratio was associated
with a history of COPD exacerbations and future exacerbations.3 Therefore, we measured
the main pulmonary artery and aorta diameters as previously described3, averaged from
four consecutive centre CT slices where the bifurcation was visible.

Figure 3-1: PA volume measurements methodology. Left panel depicts CT volume and
the level of the bifurcation (BF) where the axes of segmentation are defined from the BF
parallel to each of the MPA, LPA and RPA. The middle panel outlines a representative
slice of the segmented artery. In the right panel the segmented MPA, LPA and RPA are
shown.

3.2.5

Statistical Analysis

We used IBM SPSS Statistics for Windows v21 (IBM Corp, Armonk, NY, USA 2012) and
GraphPad Prism for Windows, v6.02 (GraphPad Software, La Jolla, CA, USA) for
statistical analyses. A one-way analysis of variance (ANOVA) with post-hoc Tukey HSD
(Honest Significant Differences) was conducted to evaluate differences between groups.
Pearson correlations were determined for pulmonary artery volumes and pulmonary
function measurements. We also performed univariate correlations for the total number of
severe exacerbations with all clinical, physiological and imaging measurements.

A

multivariate zero-inflated Poisson model was used to evaluate the relationship between the
total number of severe exacerbations with physiological and imaging measurements using
the PROC COUNTREG procedure in SAS 9.2 software (SAS Institute, Cary, NC). All
measurements with significant univariate correlations were included in the multivariate
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model.

A zero-inflated Poisson model46 was used because the total number of

hospitalizations included a large proportion of zeroes. From the significant multivariate
model, we reported the fold-change in total exacerbations which was defined as the
regression coefficient divided by the standard error. Cox regressions were conducted to
determine hazard ratios for the occurrence of first exacerbation post visit. Results were
considered significant when the probability of a type I error was less than 5% (p < .05).

Results
3.3.1

Subject Characteristics

Table 3-1 shows the demographic characteristics for the study population which was a
convenience sample of 35 never-smokers (71±7y) and 124 ex-smokers including 68 exsmokers with airflow limitation (71± 9y) and 56 ex-smokers without airflow limitation (69
±10y). One-way analysis of variance (ANOVA) showed significant differences between
the three subgroups for most parameters but not for age (p=.3) or 6MWD (p=.06). For the
two ex-smoker subgroups, there were significant differences for FEV1%pred (p<.001),
FEV1/FVC (p<.001), FRC%pred (p<.001), TLC%pred (p<.001), DLCO%pred (p<.001), VDP
(p<.001), ADC (p<.001), RA950 (p<.001), airway count (p<.001), and the main (p=.014),
right (p=.001) and total (p=.003) pulmonary artery volume.
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Table 3-1 Subject Characteristics
Never-Smokers FEV1/FVC ≥ 70% FEV1/FVC < 70% Sig.
(n=35)
(n=56)
(n=68)
Diff.
Mean (±SD)
Mean (±SD)
Mean (±SD)
p
Age yrs
71 (7)
69 (10)
71 (9)
.29
BMI kg/m2
26 (3)
29 (4)
27 (4)
<.001
Pack years
28 (17)
47 (29)
<.001
FEV1 %pred
107 (18)
98 (17)
63 (23)
<.001
FEV1/FVC %
77 (6)
80 (6)
50 (13)
<.001
FRC %pred
104 (22)
95 (19)
139 (36)
<.001
TLC %pred
100 (14)
101 (12)
118 (18)
<.001
DLCO %pred
91 (16)
79 (20)
54 (19)
<.001
SGRQ
25 (21)
40 (17)
<.001
6MWD m
401 (96)
369 (90)
.06
3
He MRI VDP %
3 (2)
6 (3)
18 (10)
<.001
3
He MRI ADC cm2/s
0.29 (0.03)
0.28 (0.04)
0.42 (0.11)
<.001
CT RA950 %
1 (1)
1 (1)
11 (11)
<.001
WA%
67 (2)
65 (2)
65 (2)
.001
Airway count
132 (40)
109 (38)
78 (29)
<.001
Main PA Volume cm3
21 (4)
24 (3)
25 (4)
<.001
3
Left PA Volume cm
8 (1)
9 (1)
10 (1)
<.001
Right PA Volume cm3
8 (1)
9 (1)
10 (2)
<.001
Total PA Volume cm3
28 (4)
31 (3)
33 (5)
<.001
BMI = Body Mass Index; FEV1 = Forced Expiratory Volume in 1 Second; %pred = Percent
Predicted; FVC = Forced Vital Capacity; FRC = Functional Residual Capacity; TLC = Total Lung
Capacity; RV = Residual Volume; DLCO = Diffusing Capacity for Carbon Monoxide; 6MWD =
Six Minute Walk Distance; VDP = Ventilation Defect Percent; ADC = Apparent Diffusion
Coefficient; RA950 = CT attenuation values below -950 HU; WA% = Wall Area Percent; PA =
Pulmonary Artery; SD = Standard Deviation; Sig. Diff. = significant difference between exsmokers with and without airflow limitation and never-smokers. Main, left, right and total PA
volumes adjusted for body surface area and age.

3.3.2

Imaging Measurements

Figure 3-2 shows qualitative results including hyperpolarized 3He MRI static ventilation
images, ADC maps, CT airway trees as well as pulmonary artery segmentations for four
representative subjects. Subject 1 is a 76y male ex-smoker with grade II COPD, significant
emphysema and ventilation defects and visibly enlarged main, left, right and total
pulmonary volume. Subject 2 is an 86y male ex-smoker with GOLD grade III COPD,
significant emphysema and ventilation defects and significantly enlarged main, left, right
and total pulmonary artery volume.
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Figure 3-2: Representative subject measurements
Subject 1 is a 76y male ex-smoker with GOLD grade II COPD and FEV1/FVC=39%,
FEV1%pred=56%, VDP=24%, ADC=0.50cm2/s, WA%=66%, main pulmonary artery
volume=29cm3, left pulmonary artery volume =11cm3, right pulmonary artery volume
=11cm3 and total pulmonary artery volume=38cm3; Subject 2 is a 86y male ex-smoker with
GOLD grade III COPD and FEV1/FVC = 35%, FEV1%pred = 38%, VDP =30%, ADC=
0.48cm2/s, WA% = 67%, main pulmonary artery volume =30cm3, left pulmonary artery
volume= 11cm3, right pulmonary artery volume = 12cm3 and total pulmonary artery
volume = 40cm3; Subject 3 is a 67y male ex-smoker FEV1/FVC=94%, FEV1%pred =103%,
VDP= 5%, ADC = 0.30cm2/s, WA% = 56%, main pulmonary artery volume =24cm3, left
pulmonary artery volume = 9cm3, right pulmonary artery volume =9cm3 and total
pulmonary artery volume=31cm3; Subject 4 is a 73y male never-smoker FEV1/FVC=76%,
FEV1%pred=122%, VDP= 2%, ADC = 0.34cm2/s, WA%=66%, main pulmonary artery
volume=20cm3, left pulmonary artery volume =8cm3, right pulmonary artery volume
=8cm3 and total pulmonary artery volume =28cm3. Scale bars=1cm.
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In contrast, Subject 3 is a 67y male ex-smoker with normal airflow measurements
(FEV1/FVC= 94%, FEV1%pred=103%) and few ventilation abnormalities concomitant with
mild emphysema (VDP=5%, ADC=0.30cm2/s) and with modest main (24 cm3), left
(9cm3), right (9cm3) and total pulmonary artery volume (31 cm3). Finally, subject 4 is a
73y male never-smoker with normal airflow, no ventilation abnormalities or emphysema,
and visibly smaller main (20cm3), left (8cm3), right (8cm3) and total pulmonary artery
volume (28cm3). Figure 3-2 shows that subjects 1 and 2 have visibly obvious ventilation
defects while for subjects 3 and 4 there is homogeneous ventilation throughout the lung.
In a similar fashion, ADC maps indicated greater emphysematous destruction in subjects
1 and 2 as compared to subjects 3 and 4. Furthermore, subjects 3 and 4 appear to report
more complete airway trees, while subjects 1 and 2, presented with truncated airway trees
that was coincident with greater pulmonary artery volumes for subjects 1 and 2 as
compared to subjects 3 and 4.

Figure 3-3 and Table 3-1 show quantitative measurements and the significant differences
in pulmonary artery volumes between ex- and never-smokers. As shown in Figure 3-3,
there were significantly greater main, left, right and total pulmonary artery volumes in exsmokers with and without airflow limitation as compared to never-smokers (p<.01). In
addition, ex-smokers with airflow limitation presented with greater main, right and total
pulmonary artery volumes compared to ex-smokers without airflow limitation (p=.01).
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Figure 3-3: PA Volume Differences between Ex-smokers and Never-Smokers. Posthoc analysis revealed significant differences between ex- and never- smokers for all PA
volumes. Significant differences in pulmonary artery volume were also observed between
ex-smokers with and without airflow limitation except for the left pulmonary artery.

3.3.3

Relationships

Table 3-2 shows Pearson Correlations for pulmonary artery volumes with measurements
of emphysema, airways disease and airflow limitation for healthy never-smokers and all
ex-smokers by subgroup.

For all subjects, there were significant correlations for

FEV1/FVC, FEV1%pred, DLCO%pred, airway count, VDP and ADC with main, left, right and
total pulmonary artery volume. For all ex-smokers, VDP was significantly correlated with
main (r=0.23, p=.009), left (r=0.20, p=.028), right (r=0.27, p=.003) and total (r=0.25,
p=.005) pulmonary artery volume and FEV1/FVC with right pulmonary artery volume
(r=-0.19, p=.03).

For ex-smokers with airflow limitation, there were no significant

correlations but in ex-smokers without airflow limitation, there were significant
correlations for main (r = 0.28, p = .037), right (r = 0.38, p = .004) and total (r = 0.32, p =
.016) pulmonary artery volume with ADC only. For never- smokers,

there

were

numerous significant correlations including for FEV1%pred with main pulmonary artery
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volume
(r=-0.37, p=.03), for FEV1/FVC with main (r=-0.36, p=.04), left (r=-0.40, p=.02), right
(r=-0.39, p=.02) and total (r=-0.39, p=.02) pulmonary artery volume, for airway count with
main pulmonary artery volume (r=-0.38, p=.026), for VDP with main (r=0.45, p=.007), left
(r=.045, p=006), right (r=0.46, p=.006) and total (r=0.46, p=.006) pulmonary artery
volume, and for ADC with left (r=0.35, p=.04), right (r=0.34, p=.045), and total (r=0.34,
p=.047) pulmonary artery volume.

Table 3-2 Pearson correlations for pulmonary artery volumes
Parameter
FEV1/FVC %
FEV1 %pred
DLCO %pred
Airway count
RA950 %
VDP %
ADC cm2/s
FEV1/FVC %
FEV1 %pred
DLCO %pred
Airway count
RA950 %
VDP %
ADC cm2/s
FEV1/FVC %
FEV1 %pred
DLCO %pred
Airway count
RA950 %
VDP %
ADC cm2/s
FEV1/FVC %
FEV1 %pred
DLCO %pred
Airway count
RA950 %
VDP %
ADC cm2/s

MPAV r (p)

LPAV r (p)
RPAV r (p)
All Subjects (n=159)
-0.26 (<.001)
-0.23 (.003)
-0.30 (<.001)
-0.24 (.002)
-0.22 (.007)
-0.23 (.004)
-0.22 (.006)
-0.21 (.009)
-0.26 (.001)
-0.31 (<.001)
-0.28 (<.001)
-0.27 (.001)
0.14 (.08)
0.15 (.07)
0.17 (.031)
0.37 (<.001)
0.35 (<.001)
0.38 (<.001)
0.21 (.008)
0.20 (.012)
0.24 (.002)
All Ex-smokers (n=124)
-0.14 (.12)
-0.09 (.33)
-0.19 (.03)
-0.02 (.82)
0.003 (.97)
-0.05 (.58)
-0.06 (.53)
-0.01 (.95)
-0.13 (.15)
-0.09 (.31)
-0.08 (.37)
-0.10 (.29)
0.03 (.73)
0.03(.77)
0.08 (.35)
0.23 (.009)
0.20 (.028)
0.27 (.003)
0.11 (.24)
0.08(.38)
0.16 (.081)
Ex-smokers FEV1/FVC < 70% (n=68)
0.18 (.13)
0.18 (.15)
0.17 (.16)
0.23 (.05)
0.24 (.05)
0.24 (.05)
0.14 (.26)
0.11 (.36)
0.09 (.45)
0.08 (.50)
0.09 (.46)
0.10 (.43)
-0.16 (.20)
-0.13 (.28)
-0.12 (.34)
0.09 (.47)
0.09 (.46)
0.09 (.46)
-0.15 (.23)
-0.13 (.29)
-0.12 (.34)
Ex-smokers FEV1/FVC ≥ 70% (n=56)
-0.07 (.59)
0.02 (.90)
-0.17 (.21)
0.10 (.45)
0.07 (.60)
0.13 (.34)
0.03 (.84)
0.12 (.39)
-0.07 (.61)
-0.07 (.60)
-0.09 (.53)
-0.05 (.69)
0.23 (.09)
0.17 (.22)
0.28 (.04)
0.23 (.09)
0.22 (.10)
0.22 (.11)
0.17 (.21)
0.28 (.037)
0.38 (.004)

TPAV r (p)
-0.28 (<.001)
-0.21 (.007)
-0.24 (.002)
-0.26 (.001)
0.16 (.042)
0.37 (<.001)
0.23 (.003)
-0.17 (.06)
-0.04 (.69)
-0.11 (.25)
-0.09 (.30)
0.07 (.43)
0.25 (.005)
0.14 (.12)
0.17 (.16)
0.24 (.05)
0.10 (.43)
0.10 (.44)
-0.12 (.33)
0.09 (.46)
-0.12 (.33)
-0.11 (.41)
0.12 (.40)
-0.01 (.94)
-0.07 (.63)
0.25 (.07)
0.23 (.10)
0.32 (.016)
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Never-Smokers (n=35)
FEV1/FVC %
-0.36 (.035)
-0.40 (.019)
-0.39 (.020)
-0.39 (.020)
FEV1 %pred
-0.25 (.15)
-0.27 (.12)
-0.27 (.11)
-0.37 (.030)
DLCO %pred
0.06 (.75)
-0.05 (.80)
-0.03 (.87)
-0.03 (.89)
Airway count
-0.24 (.16)
-0.26 (.12)
-0.27 (.11)
-0.38 (.026)
RA950 %
-0.12 (.49)
0.00 (.98)
-0.02 (.90)
-0.03 (.87)
VDP %
0.45 (.007)
0.45 (.006)
0.46 (.006)
0.46 (.006)
ADC cm2/s
0.28 (.10)
0.35 (.039)
0.34 (.045)
0.34 (.047)
FEV1 = Forced Expiratory Volume in 1 Second; DLCO = Diffusing Capacity for Carbon
Monoxide; RA950 = CT attenuation < -950 HU; VDP = Ventilation Defect Percent; ADC =
Apparent Diffusion Coefficient; MPAV = Main Pulmonary Artery Volume; LPAV = Left
Pulmonary Artery Volume; RPAV = Right Pulmonary Artery Volume; TPAV = Total Pulmonary
Artery Volume.

In the 68 COPD ex-smokers, there were four previous exacerbations in the 2.5 year period
between 5 and 2.5 years prior to the imaging visit and 46 total exacerbations in the 5 year
period between 2.5 years prior to 2.5 years post visit. Table 3-3 shows the result of a
multivariate model for predicting the total number of exacerbations in these 68 patients.
Since there were no univariate correlations for age, body surface area, RA950, WA%, 3He
MRI ADC, pulmonary artery/aorta diameter ratio, main pulmonary artery volume, and
right pulmonary artery volume with total exacerbations, they were not included in the
multivariate model.

As shown in Table 3-3, FEV1%pred was significantly (p=.004)

associated with the total number of exacerbations with a three-fold increase in the number
of total exacerbations predicted by a decrease of 1%predicted in FEV1. In addition, DLCO
was also significantly associated (p=.03) with exacerbations; a two-fold increase in total
exacerbations was predicted by an increase in DLCO of 1%predicted. Exercise capacity
(6MWD) was significantly (p=.04) associated with exacerbations; a two-fold increase in
total exacerbations was related to a one meter decrease in the distance walked. Finally,
total pulmonary artery volume was significantly (p=.03) associated with the total number
of exacerbations; for every 1cm3 increase in total pulmonary artery volume, a two-fold
increase in total exacerbations was predicted.
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Table 3-3 Relationships with total exacerbations in COPD (n=68)
Parameter (+/- SD)

Relationships With Total Exacerbations
(2.5 yrs prior to 2.5 yrs post visit)
Univariate
Multivariate Model
r (p)
Fold Change
p
Age yrs
0.15 (.23)
BSA m2
-0.07 (.58)
Previous Exacerbations (5 to 2.5 yrs prior visit)
1.75
.08
0.64 (<.001)
FEV1 %pred
-2.88
.004
-0.38 (.002)
DLCO %pred
2.12
.03
-0.26 (.034)
RV/TLC %pred
-0.87
.38
0.31 (.011)
SGRQ Score
0.05
.96
0.36 (.003)
6MWD m
-2.08
.04
-0.36 (.003)
CT RA950 %
0.19 (.12)
WA%
0.10 (.42)
Airway Count
-1.26
.21
-0.36 (.002)
3
He MRI VDP %
0.73
.46
0.32 (.008)
3
He MRI ADC cm2/s
0.14 (.25)
PA/A diameter
0.11 (.37)
3
Main PA Volume cm
0.22 (.07)
Left PA Volume cm3
-0.24
.81
0.33 (.005)
Right PA Volume cm3
0.24 (.051)
Total PA Volume cm3
2.12
.03
0.25 (.037)
BSA = Body Surface Area; FEV1 = Forced Expiratory Volume in 1 Second; DLCO = Diffusing
Capacity for Carbon Monoxide; RV = Residual Volume; TLC = Total Lung Capacity; SGRQ = St.
George’s Respiratory Questionnaire; 6MWD = Six Minute Walk Distance; RA950 = CT attenuation
values below -950 HU; WA% = Wall Area Percent of 5th generation airways; VDP = Ventilation
Defect Percent; ADC = Apparent Diffusion Coefficient; PA = Pulmonary Artery, A = Aorta;

Discussion
Our objective was to evaluate three-dimensional measurements of the pulmonary artery
derived from thoracic CT45 in a relatively small group of 159 never-smokers and exsmokers with and without COPD. We observed: 1) pulmonary artery volumes were
significantly greater in ex-smokers compared to never-smokers, and significantly greater
in ex-smokers with airflow limitation as compared to ex-smokers with normal lung
function, 2) pulmonary artery volumes were associated with pulmonary structure and
function measurements when all subjects were grouped together, and, 3) a small change of
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1cm3 in total pulmonary artery volume predicted a 2-fold change in the number of
exacerbations in 68 COPD patients.
First, we evaluated differences in pulmonary artery volumes for never-smokers and exsmokers with and without airflow limitation. We observed significantly greater pulmonary
artery volumes for ex-smokers with airflow limitation as compared to ex-smokers without
airflow limitation. This is important because previous research25 showed that pulmonary
artery size is associated with pulmonary hypertension, a relatively common finding in
COPD patients and concomitant with increased morbidity and mortality25,
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in these

patients. Furthermore, we observed significantly greater pulmonary artery volumes for exsmokers without airflow limitation as compared to never-smokers. This finding suggests
that the pulmonary arteries are abnormally enlarged even in ex-smokers without
obstruction. These results demonstrate that early or mild pulmonary abnormalities may be
present even at early stages of the disease, which may play an important role in predicting
patient outcomes.
We evaluated the relationship of the main, left, right and total pulmonary artery volume
with FEV1%pred, FEV1/FVC, DLCO%pred, as well as CT and MRI airway and emphysema
measurements. It is interesting to note that when we grouped all ex- and never-smokers
together, we observed modest correlations between pulmonary artery volumes and
measurements of lung function and structure. We also expected to observe these trends
when analyzing ex-smokers with airflow limitation alone, as previous work demonstrated
that individuals with a greater pulmonary artery to aorta diameter ratio had significantly
declined lung function.3 However, when analyzing ex-smokers with airflow limitation
alone, we did not observe significant correlations between pulmonary artery volumes and
lung function-structure measurements, suggesting that pulmonary artery enlargement may
have developed secondary to COPD in our subject group.
We also explored the relationship between pulmonary artery volumes and exacerbations of
COPD. In the resultant significant model that explained total COPD exacerbations in 68
ex-smokers with airflow limitation, previous exacerbations were not a significant predictor,
which was surprising in light of previous work.26 However, the number of previous
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exacerbations was likely not a predictor of total exacerbations as only a single subject
experienced 4 previous exacerbations (between 5 years and 2.5 years prior to study).
Consistent with previous work that showed the association between 6MWD and COPD
hospitalization48,

we observed that the 6MWD was a significant predictor in our

multivariate model and reported that a 1m decrease in 6MWD resulted in a two-fold
increase in total exacerbations. While in our study, FEV1%pred was associated with a 3fold increase in total exacerbations, previous studies showed that FEV1 correlated weakly
with clinical symptoms including cardiovascular disease and exacerbation frequency.49, 50
Total pulmonary artery volume was significantly (p=.03) associated with exacerbations
while the PA:A ratio which was associated with acute exacerbations of COPD in the
COPDGene (n = 3464) and ECLIPSE (n = 2005) studies3 was not significant in our model.
This suggests that the three-dimensional total pulmonary artery volume measurement may
have a stronger association with COPD exacerbations than the PA:A ratio.
It is important to address the limitations that we encountered throughout this work. First,
we must acknowledge that subject groups consisted of a relatively small sample size as
compared to previous studies using the one-dimensional measurement.3 Our study was
limited to and only included those exacerbations that required hospitalizations. Based on
a previous study, about 50% of exacerbations go unreported5 and such events should be
considered in future studies as they may provide additional information when predicting
future exacerbations. Several studies have shown the relationship between pulmonary
artery size and pulmonary hypertension23-25, 51-54. It has also been shown that individuals
with pulmonary hypertension have an increased risk of experiencing a COPD
exacerbation.48 While we sought to explore the relationship between pulmonary artery
enlargement and COPD, it may be of importance to also include pulmonary artery pressure
measurements in future analyses. Unfortunately, right-heart catheterization data was not
acquired for this group of patients and therefore pulmonary artery pressures could not be
directly measured and included in our analyses.

64

In summary, we demonstrated that pulmonary artery volume changes may develop in very
early or subclinical stages of COPD. We also showed that total pulmonary artery volume
predicted COPD exacerbations, in a relatively small number of COPD patients in whom
there were very few previous exacerbations.
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CHAPTER 4: CONCLUSIONS AND FUTURE WORK
Summary
COPD exacerbations are severe events that result in decreased health-related quality of life
and contribute to increased morbidity and greater mortality rates.1, 2 Exacerbations are also
of major impact on our healthcare system, as hospitalizations associated with treatment of
these events are costly.3-5 It has been previously shown that the frequency of exacerbations
increases with the severity of COPD and that this is an independent determinant of healthrelated patient quality of life.1, 2 Biomarkers for predicting the occurrence of exacerbations
have not been well established; however, numerous studies have outlined several risk
factors, such as a decreased exercise capacity, that are associated with a higher
exacerbation frequency.6-8 In particular, Hurst et al. demonstrated that, in a group of 2138
subjects, the single best predictor of future exacerbations was the occurrence of previous
exacerbations. This was consistent in COPD patients across GOLD severity grades.7 A
further study by Wells et al., which included 3464 subjects from the COPDGene study as
well as 2005 individuals from the ECLIPSE study, showed that a pulmonary artery to aorta
diameter ratio >1 was associated with a history of acute exacerbations.8 Furthermore, this
ratio was associated with risk factors of future exacerbations.8 However, this study was
limited in that it relied on a simple one-dimensional diameter measurement. We believe
that such a measurement is not sensitive to three-dimensional morphological changes of
the pulmonary vasculature, as morphological changes could vary in different dimensions.
A three-dimensional volumetric measurement approach would be more sensitive in
quantifying changes in pulmonary artery size because it would account for morphological
changes in all three Cartesian planes and would take into consideration a larger section of
the vessel.
Therefore, the objectives of this thesis were the following: 1) to develop a threedimensional technique for assessing the size of the main, left and right pulmonary arteries;
2) to determine the inter- and intra-observer reducibility of our approach; 3) to determine
associations between pulmonary artery volumes and COPD; and, 4) to evaluate pulmonary
artery volumes as useful biomarkers for predicting COPD exacerbations.
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In Chapter 2, we address objective 1 which focuses on the development of a threedimensional volumetric technique and on the assessment of its inter- and intra-observer
reproducibility. Briefly, to determine the volume, we manually outlined the cross-sectional
area of each artery in a series of slices perpendicular to the longitudinal axis of the vessel.
Summing the products of each area and inter-slice distance resulted in a volume
measurement for each vessel. Total pulmonary artery volume was also calculated by taking
the union of voxels enclosed by each of the three vessels and multiplying it by the voxel
dimensions. From five rounds of repeated measurements, performed by three observers,
we showed that our technique was highly reproducible, with strong inter- and intraobserver agreement between measurements.

To assess the inter- and intra-observer

agreement, the coefficient of variation as well as the intraclass correlation coefficient was
calculated from the five repeated rounds of measurements. We also showed strong
agreement between baseline and follow-up measurements performed by the same observer
with four months between measurements.
In Chapter 3, we address objective 2, which focuses on evaluating PA abnormalities in a
group of ex-smokers. Specifically, we: 1) compared pulmonary artery sizes between a
group of never-smokers and a group of ex-smokers; 2) assessed the relationship between
pulmonary artery volumes and measurements of lung function and structure; and, 3)
assessed pulmonary artery volumes as potential biomarkers for predicting the occurrence
of acute exacerbations. We hypothesized that pulmonary artery volumes will be greater in
ex-smokers as compared to never-smokers. We expected pulmonary artery volumes to
correlate with measurements of lung function and structure and that they would be a
suitable biomarker for predicting exacerbations of COPD. We observed that ex-smokers
presented with higher artery volumes than did the never-smoker subject group. When all
ex-smokers were grouped together, we found significant positive correlations between
VDP and MPA, LPA, RPA and TPA volumes. Furthermore, multivariate regression
analysis revealed total pulmonary artery volume to be a significant predictor of COPD
exacerbations; however, this relationship should be tested in different subject groups to
strengthen our finding.
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Limitations of Current Work
It is important that we report the limitations that were encountered in developing the
volumetric technique described in Chapter 2 as well as the clinical relationships described
in Chapter 3. Although measurements were reproducible with high inter- and intraobserver agreement, when examining measurements performed by each observer in more
detail, we found that most of the variability between measurements resulted from the angle
at which the axes of segmentation were placed. Better anatomical landmarks should be
considered when placing the axes of segmentation to further improve the reproducibility
of our technique. Furthermore, manual segmentation makes this technique time consuming
and laborious. Automation of the technique would address this limitation. Moreover, we
must acknowledge the fact that the computed tomography images acquired for our subjects
were intended for emphysema measurements of the lung. For this reason, in several images
it was difficult to distinguish the pulmonary artery from the surrounding tissue. Contrast
imaging using an iodine-based contrast agent would allow the pulmonary artery to be better
defined from the surroundings and potentially improve the reproducibility of our technique.
When assessing the relationship between pulmonary artery volumes and measurements of
lung function and structure, we must acknowledge that our subject groups consisted of a
relatively small sample size as compared to previous studies using the one-dimensional
measurement.8 Thus, our technique should be extended to different subject groups to
evaluate its association with COPD and its ability to predict exacerbations. Furthermore,
14 subjects were excluded from our analyses due to poor image quality, which often
resulted from poor contrast between the pulmonary arteries and the surrounding tissue.
Our study was limited to and only included those exacerbations that required
hospitalizations. Based on a previous study, about 50% of exacerbations go unreported.
These events should be considered and included in future analyses. Several studies have
shown the relationship between pulmonary artery size and pulmonary hypertension.9-15 It
has also been shown that individuals with pulmonary hypertension have an increased risk
of experiencing a COPD exacerbation.6 While we sought to explore the relationship
between pulmonary artery enlargement and COPD, it may be of importance to also include
pulmonary artery pressure measurements in future analyses. Unfortunately, right-heart
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catheterization data was not collected for this group of patients and therefore pulmonary
artery pressures could not be directly measured and included in our analyses.

Future work and Clinical Applications
As previously mentioned, when assessing the relationship between pulmonary artery size
and COPD, we were limited by a relatively small sample size for both the ex-smoker and
the never-smoker subject group. Wells et al. explored the relationship between pulmonary
artery diameter and exacerbations in a large number of subjects.8 Future studies should
consider assessing the relationship between pulmonary artery volumes and COPD
exacerbations in a large number of subjects as well as in different subject groups, including
healthy individuals.
To our knowledge we are the first to consider a three-dimensional technique for assessing
the size of the main, left and right pulmonary arteries. As mentioned before, manual sliceby-slice segmentation of the pulmonary arteries in cross-sectional planes to each vessel are
time consuming and laborious. The time taken to perform main, left and right pulmonary
artery volume measurements for a single subject can take up to one hour. The extensive
amount of time required to analyze a single individual makes our technique unsuitable for
large scale clinical trials. Therefore, future work should focus on improving our technique
by developing semi-automated or fully-automated algorithms to estimate the size of the
pulmonary arteries. Automation of this technique will reduce the user input required and
would therefore significantly decrease the time taken to perform a measurement. Such an
improvement would allow pulmonary artery volumes to be measured in studies with larger
sample sizes. The use of iodine-based contrast agents may be considered in future studies
to improve the contrast between the pulmonary arteries and the surrounding tissues. This,
in turn, may help with developing an appropriate automated algorithm which estimates the
size of the pulmonary artery on a specific threshold and boundaries set by the user.
Pulmonary hypertension is a known complication of COPD that results in an increase in
morbidity and mortality.16 The current gold standard for assessing pulmonary hypertension
is through right heart catheterization.9

This technique is invasive, generally causes
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discomfort, and can lead to complications. Recent studies have shown that the diameter of
the pulmonary artery measured at the level of the bifurcation has the ability to predict
borderline pulmonary hypertension.9-15 We believe that our three-dimensional volumetric
technique may be more sensitive to morphological changes in the pulmonary artery and
should therefore be assessed as a potential diagnostic tool in predicting pulmonary
hypertension. This would provide a non-invasive method for assessing and monitoring
patients at risk of pulmonary hypertension. Therefore, future studies should assess the
relationship between pulmonary artery pressures measured by right heart catheterization
and pulmonary artery volumes measured using our technique.
Future studies should also focus on developing MRI imaging techniques for evaluating the
size of the pulmonary arteries. This development would allow for repeated measurements
to be performed and would therefore permit evaluation of disease progression and
treatment response. MRI provides high soft tissue contrast which may yield useful
information in developing future measurements of the pulmonary arteries. Being able to
differentiate between the lumen of the vessel and the arterial wall could reveal useful
information about pulmonary artery abnormalities.
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